27 Results for "

Colon adenocarcinoma model

" in MedChemExpress (MCE) Product Catalog:
Products (27)

27 Results for "Colon adenocarcinoma model" in MCE Product Catalog:

32
32 Publications Verification
Cat. No.: HY-10459
CAS No.: 717907-75-0
Purity:  99.68%
Synonyms: VS-6062
Target:  

FAK Pyk2

PF-562271 (VS-6062) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .
loading...
    loading...
32
32 Publications Verification
Cat. No.: HY-10458
CAS No.: 939791-38-5
Purity:  99.17%
Synonyms: VS-6062 (besylate)
Target:  

FAK Pyk2

PF-562271 besylate (VS-6062 besylate) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 besylate induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 besylate exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 besylate reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 besylate can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-20403
CAS No.: 939791-41-0
Synonyms: VS-6062hydrochloride
Target:  

FAK Pyk2

PF-562271 hydrochloride (VS-6062 hydrochloride) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 hydrochloride induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 hydrochloride exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 hydrochloride reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 hydrochloride can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2445
CAS No.: 37308-75-1
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .
loading...
    loading...
Cat. No.: HY-152830
CAS No.: 2394874-66-7
Purity:  99.51%
Synonyms: Q702
Target:  

c-Fms TAM Receptor MHC

Research Areas:  

Cancer

Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
loading...
    loading...
Cat. No.: HY-50914
CAS No.: 924641-59-8
Target:  

CDK

Research Areas:  

Cancer

AZD5597 is an inhibitor of CDK with IC50 values of both 2 nM for CDK1 and CDK2. AZD5597 can inhibit the proliferation of tumor cells and has anti-tumor activity .
loading...
    loading...
Cat. No.: HY-173178
CAS No.: 925419-55-2
Research Areas:  

Cancer

LNS8801 is an orally active GPER activator with tumor suppressor activity. LNS8801 mediates suppression of cancer via GPER activation, with activity dependent on GPER expression. LNS8801 suppresses cancer growth in preclinical models. LNS8801 can be used for the research of cancer (including melanoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer, leukemias, colon carcinomas) .
loading...
    loading...
Cat. No.: HY-76558
CAS No.: 5909-24-0
Ethyl 4-chloro-2-(methylthio) pyrimidine-5-carboxylate is a pharmaceutical intermediate. Ethyl 4-chloro-2-(methylthio) pyrimidine-5-carboxylate can be used to synthesize inhibitors of various kinases (e.g., Cdk4, PDGF, FGF, EGF). Ethyl 4-chloro-2-(methylthio) pyrimidine-5-carboxylate is applicable to research related to cancer and fungal infections .
loading...
    loading...
Cat. No.: HY-W585827
CAS No.: 497-04-1
Synonyms: 2-MCPD
Target:  

Drug Derivative

Research Areas:  

Others

2-Chloro-1,3-propanediol (2-MCPD) is a pharmaceutical intermediate. 2-Chloro-1,3-propanediol is a common glycerol-derived chemical intermediate and also a food processing contaminant. 2-Chloro-1,3-propanediol can cross the intestinal barrier model via paracellular diffusion. 2-Chloro-1,3-propanediol induces renal and testicular toxicity in animal models. 2-Chloro-1,3-propanediol can be used in research related to organic synthesis .
loading...
    loading...
Cat. No.: HY-156249
CAS No.: 1466546-45-1
NMS-P528 is a DNA minor groove alkylating agent and ADC payload. NMS-P528 undergoes intramolecular cyclization to form reactive electrophilic derivatives, which in turn induce DNA damage, cell cycle arrest, and Apoptosis. NMS-P528 shows no significant anti-tumor activity as a free payload in a HER2-negative Raji lymphoma mouse xenograft model. NMS-P528 serves as the cytotoxic payload for the antibody-drug conjugate EV20/NMS-P945. NMS-P528 can be used in research related to breast cancer, gastric cancer, colon adenocarcinoma, Burkitt's lymphoma, neuroblastoma, pancreatic cancer, prostate cancer, head and neck cancer, ovarian cancer, and melanoma .
loading...
    loading...
Cat. No.: HY-10823
CAS No.: 139987-54-5
Synonyms: GW1843; 1843U89; OSI-7904
Research Areas:  

Cancer

OSI-7904L (GW1843; 1843U89; OSI-7904) is a thymidylate synthase (TS) inhibitor with a Ki of 90 pM. OSI-7904L blocks de novo synthesis of thymidine nucleotides, DNA synthesis and induces cell death. OSI-7904L inhibits the growth of human cells, induces tumor regression, and achieves durable antitumor effects in mouse xenograft models. OSI-7904L can be used in research related to colon adenocarcinoma .
loading...
    loading...
Cat. No.: HY-152830A
Purity:  99.82%
Synonyms: Q702 TFA
Target:  

c-Fms TAM Receptor MHC

Research Areas:  

Cancer

Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
loading...
    loading...
Cat. No.: HY-W585827S
CAS No.: 1216764-05-4
Synonyms: 2-MCPD-d5
2-Chloro-1,3-propanediol-d5 (2-MCPD-d5) is the deuterated-labeled 2-Chloro-1,3-propanediol (HY-W585827). 2-Chloro-1,3-propanediol (2-MCPD) is a pharmaceutical intermediate. 2-Chloro-1,3-propanediol is a common glycerol-derived chemical intermediate and also a food processing contaminant. 2-Chloro-1,3-propanediol can cross the intestinal barrier model via paracellular diffusion. 2-Chloro-1,3-propanediol induces renal and testicular toxicity in animal models. 2-Chloro-1,3-propanediol can be used in research related to organic synthesis .
loading...
    loading...
Cat. No.: HY-W585827S1
CAS No.: 1216764-05-4
Synonyms: 2-MCPD-d5 (major)
2-Chloro-1,3-propanediol-d5 (major) (2-MCPD-d5 (major)) is the deuterated-labeled 2-Chloro-1,3-propanediol (HY-W585827). 2-Chloro-1,3-propanediol (2-MCPD) is a pharmaceutical intermediate. 2-Chloro-1,3-propanediol is a common glycerol-derived chemical intermediate and also a food processing contaminant. 2-Chloro-1,3-propanediol can cross the intestinal barrier model via paracellular diffusion. 2-Chloro-1,3-propanediol induces renal and testicular toxicity in animal models. 2-Chloro-1,3-propanediol can be used in research related to organic synthesis .
loading...
    loading...
Cat. No.: HY-P990610

Target:  

Akt mTOR PI3K

Research Areas:  

Cancer

KHK-2898 is a monoclonal antibody targeting CD98, which binds to the extracellular domain of CD98 on the tumor cell membrane in a non-covalent antigen-specific mode. KHK-2898 can disrupt the heterodimeric complex formed by CD98 with LAT1 and xCT light chains, reduce the amino acid uptake capacity of tumor cells, block the PI3K/AKT/mTOR proliferative signaling cascade, and mediate antibody-dependent cytotoxicity. KHK-2898 can be used for cancer-related research. The isotype control of KHK-2898 can be found in Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-111251
CAS No.: 871015-11-1
Research Areas:  

Cancer

4SC-207 is a potent, orally active microtubule inhibitor. 4SC-207 inhibits microtubule growth to inhibit tumor cell proliferation in vitro and in vivo, and promotes a mitotic delay/arrest, followed by apoptosis or aberrant divisions. 4SC-207 inhibits tumor growth in taxane resistant xenograft mouse models. 4SC-207 can be used for cancer research, such as colon adenocarcinoma and other malignancies .
loading...
    loading...
Cat. No.: HY-185098
CAS No.: 2007110-15-6
Research Areas:  

Cancer

PD1-PDL1-IN-4 (compound 19) is a potent and orally active PD1-PDL1 inhibitor that modulates TIGIT and PD-1 signalling pathways. PD1-PDL1-IN-4 can rescue CD8 + T cell and mouse splenocyte proliferation. PD1-PDL1-IN-4 inhibits tumor growth in a CT26 syngeneic colon adenocarcinoma mouse model. PD1-PDL1-IN-4 can be used for research on colon cancer .
loading...
    loading...
Cat. No.: HY-182241
CAS No.: 2446965-01-9
JR4-187 is an orally active, copper-dependent anticancer agent. JR4-187 downregulates genes involved in oxidative phosphorylation, MYC targets and E2F targets in cancer cells, while upregulates genes involved in the TNF-α signaling pathway, p53 pathway and KRAS signaling pathway, and downregulates CTR1 protein . JR4-187 induces ROS production, apoptosis, copper-dependent cytotoxicity, and exhibits selective cytotoxicity against KRAS-mutant cancer cells. JR4-187 is well tolerated in mouse models of pancreatic cancer. JR4-187 can be used in research related to cancers such as pancreatic ductal adenocarcinoma, colon cancer and rectal cancer .
loading...
    loading...
Cat. No.: HY-182387
CAS No.: 208986-26-9
Research Areas:  

Cancer

NM404 is a targeted radionuclide processing agent with slow clearance. Radioiodine-labeled NM404 is a small-molecule phospholipid ether analog that exhibits significant tumor uptake capacity and persistent tumor retention properties in more than 45 spontaneous and xenograft tumor models .
loading...
    loading...
Cat. No.: HY-10459A
CAS No.: 939791-39-6
Synonyms: VS-6062 mesylate
Target:  

FAK Pyk2

Research Areas:  

Neurological Disease Cancer

PF-562271 mesylate (VS-6062 mesylate) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 mesylate induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 mesylate exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 mesylate reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 mesylate can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma .
loading...
    loading...